{
    "clinical_study": {
        "@rank": "21828", 
        "acronym": "RAD2412-13", 
        "arm_group": {
            "arm_group_label": "Soy isoflavone", 
            "arm_group_type": "Experimental", 
            "description": "Study Treatment:Soy Isoflavone in combo w/ Radiation Therapy & Cisplatin"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if soy supplementation during chemotherapy and\n      radiation therapy will decrease side effects caused by treatment. Long-lasting dry mouth is\n      a side effect of the standard treatment, and we are testing whether soy supplementation\n      during treatment may reduce this symptom and other side effects of chemoradiation."
        }, 
        "brief_title": "Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck", 
        "completion_date": {
            "#text": "April 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer of Head and Neck", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Concurrent chemoradiation is the standard of care for locally advanced squamous cell\n      carcinoma of the head and neck (SCCHN). Improving the outcome for patients with this disease\n      remains a major challenge."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy proven SCCHN\n\n          -  Primary disease site involving the  oropharynx\n\n          -  Clinical stage III or IV\n\n          -  Age \u2265 18\n\n          -  Karnofsky Performance Status (KPS) \u2265 70\n\n          -  Electrolytes, hepatic, renal, and hematologic functions within normal limits\n\n          -  Amylase  and lipase levels within normal limits\n\n        Exclusion Criteria:\n\n          -  Prior history of SCCHN\n\n          -  Prior history of radiation to the head and neck region\n\n          -  KPS< 70\n\n          -  Soy allergy\n\n          -  Contraindication to Cisplatin chemotherapy or plans to alter or reduce Cisplatin\n             therapy\n\n          -  Any head and neck cancer of non-squamous histology\n\n          -  Any head and neck subsite other than oropharynx (including unknown primary site)\n\n          -  Patients who are pregnant or lactating\n\n          -  Patients who may benefit from surgical resection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075112", 
            "org_study_id": "IRB00065591"
        }, 
        "intervention": {
            "arm_group_label": "Soy isoflavone", 
            "description": "Study Treatment:Soy Isoflavone in combo w/Radiation Therapy & Cisplatin", 
            "intervention_name": "soy isoflavone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Soy", 
            "Isoflavone", 
            "Radiation Therapy", 
            "Cisplatin"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "contact": {
                "email": "jhuaman@emory.edu", 
                "last_name": "Jessica M Huamani- Bundy, MS", 
                "phone": "404-778-5720"
            }, 
            "contact_backup": {
                "last_name": "Chade Granderson, BS", 
                "phone": "404-778-3609"
            }, 
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30322"
                }, 
                "name": "Emory University Winship Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Kristin Higgins, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck", 
        "overall_contact": {
            "email": "kristin.higgins@emory.edu", 
            "last_name": "Kristin Higgins, MD", 
            "phone": "404-778-1900"
        }, 
        "overall_contact_backup": {
            "email": "jhuaman@emory.edu", 
            "last_name": "Jessica M Huamani-Bundy, MS", 
            "phone": "404-778-5720"
        }, 
        "overall_official": {
            "affiliation": "Emory University", 
            "last_name": "Kritin Higgins, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome of this study is the percentage of patients with symptomatic (grade 2 or higher) xerostomia at 1 year post-treatment, assessed by the LENT/SOMA method.", 
            "measure": "Percentage of patients with grade  2 or higher xerostomia at 1 year post-treatment.", 
            "safety_issue": "No", 
            "time_frame": "1 year after treatment completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075112"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Emory University", 
            "investigator_full_name": "Kristin Higgins, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Baseline tissue levels of p16, COX-2, EGFR, and NF-kB and look for any correlations of these proteins with clinical parameters of outcome and toxicity\nBaseline urinary levels of isoprostanes before treatment, and 3 and 6 months post- treatment, as a potential marker of oxidative stress associated with chemoradiation.", 
            "measure": "Exploratory biomarker studies", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "source": "Emory University", 
        "sponsors": {
            "collaborator": {
                "agency": "Radiation Therapy Oncology Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Emory University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}